Repository logo
 

Pharmacological targeting of endoplasmic reticulum stress in disease.

Simple item page
cam.issuedOnline2021-10-26
cam.orpheus.success2021-11-08 - Embargo set during processing via Fast-track
dc.contributor.authorMarciniak, Stefan J
dc.contributor.authorChambers, Joseph E
dc.contributor.authorRon, David
dc.contributor.orcidMarciniak, Stefan J [0000-0001-8472-7183]
dc.contributor.orcidChambers, Joseph E [0000-0003-4675-0053]
dc.contributor.orcidRon, David [0000-0002-3014-5636]
dc.date.accessioned2021-11-09T00:31:12Z
dc.date.available2021-11-09T00:31:12Z
dc.date.issued2022-02
dc.description.abstractThe accumulation of misfolded proteins in the endoplasmic reticulum (ER) leads to ER stress, resulting in activation of the unfolded protein response (UPR) that aims to restore protein homeostasis. However, the UPR also plays an important pathological role in many diseases, including metabolic disorders, cancer and neurological disorders. Over the last decade, significant effort has been invested in targeting signalling proteins involved in the UPR and an array of drug-like molecules is now available. However, these molecules have limitations, the understanding of which is crucial for their development into therapies. Here, we critically review the existing ER stress and UPR-directed drug-like molecules, highlighting both their value and their limitations.
dc.identifier.doi10.17863/CAM.77921
dc.identifier.eissn1474-1784
dc.identifier.issn1474-1776
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/330477
dc.languageeng
dc.language.isoeng
dc.publisherSpringer Science and Business Media LLC
dc.publisher.urlhttp://dx.doi.org/10.1038/s41573-021-00320-3
dc.rightsAll rights reserved
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserved
dc.subjectAnimals
dc.subjectEndoplasmic Reticulum Stress
dc.subjectHumans
dc.subjectMetabolic Diseases
dc.subjectNeoplasms
dc.subjectNervous System Diseases
dc.subjectUnfolded Protein Response
dc.titlePharmacological targeting of endoplasmic reticulum stress in disease.
dc.typeArticle
dcterms.dateAccepted2021-09-15
prism.publicationDate2021
prism.publicationNameNat Rev Drug Discov
pubs.funder-project-idWellcome Trust (100140/Z/12/Z)
pubs.funder-project-idWellcome Trust (200848/Z/16/Z)
pubs.funder-project-idMedical Research Council (MR/R009120/1)
pubs.funder-project-idMRC (MR/V028669/1)
pubs.funder-project-idNational Institute for Health and Care Research (IS-BRC-1215-20014)
pubs.funder-project-idMedical Research Council (G1002610)
pubs.funder-project-idEngineering and Physical Sciences Research Council (EP/S009000/1)
rioxxterms.licenseref.startdate2021-10-26
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.typeJournal Article/Review
rioxxterms.versionAM
rioxxterms.versionofrecord10.1038/s41573-021-00320-3

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Marciniak_final_edit_1630430770_85_SM4.docx
Size:
757.83 KB
Format:
Microsoft Word XML
Description:
Accepted version
Licence
http://www.rioxx.net/licenses/all-rights-reserved
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
DepositLicenceAgreementv2.1.pdf
Size:
150.9 KB
Format:
Adobe Portable Document Format
Download

Collections

Cambridge University Research Outputs